Ibogaine in the treatment of substance dependence

Current Drug Abuse Reviews

Volumn 6, Issue 1, 2013, Pages 3-16

  Brown, Thomas Kingsley ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; Addiction treatment; Drug abuse; Iboga alkaloid; Ibogaine; Psychedelics; Substance related disorders

Indexed keywords

18 METHOXYCORONARIDINE; IBOGAINE; METHADONE; NORIBOGAINE;

ALCOHOLISM; ATAXIA; BRADYCARDIA; CLINICAL EFFECTIVENESS; COCAINE DEPENDENCE; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; HEROIN DEPENDENCE; HUMAN; METHADONE TREATMENT; METHAMPHETAMINE DEPENDENCE; MORPHINE ADDICTION; NAUSEA; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; QT PROLONGATION; RELAPSE; REVIEW; SINGLE DRUG DOSE; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TREATMENT DURATION; TREMOR; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ADDICTIVE; DISEASE MODELS, ANIMAL; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IBOGAINE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 84880166473     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/15672050113109990001     Document Type: Review

References (109)

1. Fernandez JW. Bwiti: an ethnography of the religious imagination in Africa. Princeton, New Jersey: Princeton University Press 1982.
2. Alper KR. Ibogaine: a review. Alkaloids Chem Biol 2001; 56: 1-38.
3. Alper KR, Lotsof HS. The use of ibogaine in the treatment of addictions. In: Winkelman WJ, Roberts TB, Eds. Psychedelic medicine. Westport, Connecticut: Praeger 2007; pp 43-66.
4. Mash DC. Ibogaine therapy for substance abuse disorders. In: Brizer D, Castaneda R, Eds. Clinical addiction psychiatry. Cambridge: Cambridge University Press 2010; pp 50-60.
5. Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol 2008; 115(1): 9-24.
6. Goutarel R, Gollnhoffer O, Sillans R. Pharmacodynamics and therapeutic applications of iboga and ibogaine. Psychedelic Monographs and Essays 1993; 6: 71-111.
7. Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci 2012; 57(2): 398-412.
8. Alper KR, Beal D, Kaplan CD. A contemporary history of ibogaine in the United States and Europe. Alkaloids Chem Biol 2001; 56: 249-81.
9. Lotsof HS, Alexander NE. Case studies of ibogaine treatment: implications for patient management strategies. Alkaloids Chem Biol 2001; 56: 293-313.
10. Lotsof HS. Ibogaine in the treatment of chemical dependence disorders: clinical perspectives. Newsletter of the Multidisciplinary Association for Psychedelic Studies (MAPS) 1995; 5(3): 16-27.
11. Lotsof HS, inventor. Rapid method for interrupting the narcotic addiction syndrome. United States patent US 4499096 1985.
12. Lotsof HS, inventor. Rapid method for interrupting the cocaine and amphetamine abuse syndrome. United States patent US 4587243 1986.
13. Lotsof HS, inventor. Rapid method for attenuating the alcohol dependency syndrome. United States patent US 4857523 1989.
14. Lotsof HS, inventor. Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome. United States patent US 5026697 1991.
15. Lotsof HS, inventor. Rapid method for interrupting the polysubstance abuse syndrome. United States patent US 5152995 1992.
16. Schneider JA, inventor; Ciba Pharmaceutical Products Inc, Summit, NJ, assignee. Tabernanthine, ibogaine containing analgesic compositions. United States patent US 2817623 1957.
17. Naranjo C. The healing journey: new approaches to consciousness. New York City: Pantheon Books, Division of Random House 1974.
18. Stolaroff M. The secret chief: conversations with a pioneer of the underground psychedelic therapy movement. Charlotte, North Carolina: Multidisciplinary Association for Psychedelic Studies 1997.
19. Stolaroff M. The Secret Chief Revealed: conversations with Leo Zeff, pioneer in the underground psychedelic therapy movement. Sarasota, Florida: Multidisciplinary Association for Psychedelic Studies 2004.
20. Dzoljic ED, Kaplan CD, Dzoljic MR. Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphinedependent rats. Arch Int Pharmacodyn Ther 1988; 294: 64-70.
21. Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN. Effects and aftereffects of ibogaine on morphine selfadministration in rats. Eur J Pharmacol 1991; 195: 341-5.
22. Glick SD, Gallagher CA, Hough LB, Rossman KL, Maisonneuve IM. Differential effects of ibogaine pretreatment on brain levels of morphine and (+)-amphetamine. Brain Res 1992; 588: 173-6.
23. Schmidt WK, Gorodetzky CW, Teti NL, Vocci F, Grossman SA, Mansbach RS. Drug abuse pharmacotherapy development in the private sector. Proceedings of the 60th Annual Meeting, The College of Problems on Drug Dependence; 1998 June; Scottsdale, Arizona. Bethesda, Maryland: US Department of Health & Human Services 1999; p 20.
24. Vastag B. Ibogaine therapy: a 'vast, uncontrolled experiment.' Science 2005; 308(5720): 345-6.
25. Erowid.org [homepage on the Internet]. [cited 2012 June 11]. Available from: http://www.erowid.org
26. Montagne M. Sites of substance: internet "drug" resources. Substance Use and Misuse 2008; 43: 17-25.
27. Brown TK and Gorenflo K. Ibogaine treatment for drug dependence: a study of quality of life [video on the Internet; cited 2012 May 30]. Presentation at Psychedelic Science in the 21st Century; 2010 April 15-18; San Jose, CA. Available from http://www.maps.org/videos/source5/
28. Brown TK. Ibogaine research in opiate addicts [video on the Internet; cited 2012 July 3]. Presentation at Cartographie Psychedelica Conference; 2011 Dec 8-12; Oakland, CA. Available from http://www.maps.org/media/videos_25/
29. Lotsof HS, Wachtel B. Manual for ibogaine therapy screening, safety, monitoring, and aftercare. [monograph on the Internet; © 2003; cited 2012 July 12]. Available from http://www.ibogaine.desk.nl/manual.html
30. Biichi G, Coffen DL, Kocsis K, Sonnet PE, Ziegler FE. The total synthesis of iboga alkaloids. J Amer Chem Soc 1966; 88(13): 3009-108.
31. Shulgin A, Shulgin A. TiKHAL: the continuation. Lafayette, CA: Transform Press 1997.
32. Janot MM, Goutarel R. Derivatives of the ibogaine alkaloids. Unites States patent US 2813873 1957 Nov 19.
33. Halpern JH. Hallucinogens: an update. Current Psychiatry Reports 2003; 5(5): 347-54.
34. Mash DC, Kovera CA, Buck BE, et al. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann NY Acad Sci 1998; 844: 274-92.
35. Mash DC, Kovera CA, Pablo J, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol 2001; 56: 155-71.
36. Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol 2008; 27(3): 181-94.
37. Maisonneuve IM, Glick SD. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacol Biochem Behav 2003; 75(3): 607-18.
38. Glick SD, Maisonneuve IM. Development of novel medications for drug addiction. The legacy of an African shrub. Ann N Y Acad Sci 2000; 909: 88-103.
39. Vastag, Addiction Treatment Strives for Legitimacy. Journal of the American Medical Association 2002; 288: 3096-101.
40. Cappendijk TSL, Dzoljic MR. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol 1993; 241(2-3): 261-5.
41. Dworkin SI, Gleeson S, Meloni D, Koves TR, Martin TJ. Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats. Psychopharmacol 1995; 117(3): 257-61.
42. Glick SD, Kuehne ME, Raucci J, et al. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res 1994; 657(1-2): 14-22.
43. Glick SD, Kuehne ME, Maisonneuve IM, Bandarage UK, Molinari HH. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res 1996; 719: 29-35.
44. Sershen H, Hashim A, Lajtha A. Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacol Biochem Behav 1994; 47(1) 13-9.
45. Rezvani AH, Overstreet DH, Lee YW. Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring mice. Pharmacol Biochem Behav 1995; 52(3): 615-20.
46. He DY, McGough NN, Ravindranathan A, et al. Glial cell linederived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 2005; 25(3): 619-28.
47. Glick SD, Maisonneuve IM, Visker KE, Fritz KA, Bandarage UK, Kuehne ME. 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology 1998; 139(3): 274-80.
48. Glick SD, Maisonneuve IM, Pearl SM. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res 1997; 749(2): 340-3.
49. Zubaran C. Ibogaine and noribogaine: comparing parent compound to metabolite. CNS Drug Reviews 2000; 6(3): 219-240.
50. Baumann MH, Rothman RB, Pablo JP, Mash DC. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 2001; 297(2): 531-9.
51. Glick SD, Pearl SM, Cai J, Maisonneuve IM. Ibogaine-like effects of noribogaine in rats. Brain Res 1996; 713(1-2): 294-7.
52. Carnicella S, He DY, Yowell QV, Glick SD and Ron D. Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addict Biol 2010; 15(4): 424-33.
53. Pearl SM, Hough LB, Boyd DL, Glick SD. Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism. Pharmacol Biochem Behav 1997; 57(4): 809-15.
54. Glick, SD, Maisonneuve, IM, Dickinson HA. 18-MC reduces methamphetamine and nicotine self-administration in rats. Neuroreport 2000; 11: 2013-15.
55. Rezvani AH, Overstreet DH, Yang Y, et al. Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol Biochem Behav 1997; 58: 615-9.
56. Rho B, Glick SD. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats. Neuroreport 1998; 9(7): 1283-5.
57. Maisonneuve IM, Keller RW Jr, Glick SD. Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. Eur J Pharmacol 1991; 199(1): 35-42.
58. Frances B, Gout R, Cros J, Zajac JM. Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice. Fundam Clin Pharmacol 1992; 6(8-9): 327-32.
59. Aceto MD, Bowman ER, Harris LS, May EL. Dependence studies of new compounds in the rhesus monkey and mouse. NIDA Res Monogr 1992; 119: 513-58.
60. Sharpe LG, Jaffe JH. Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine-dependent rat. Neuroreport 1990; 1(1): 17-9.
61. Cappendijk SL, Fekkes D, Dzoljic MR. The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine. Behav Brain Res 1994; 65(1): 117-9.
62. Popik P, Layer RT, Fossom LH, et al. NMDA antagonist properties of the putative anti-ad-dictive drug, ibogaine. J Pharmacol Exp Ther 1995; 275(2): 753-60.
63. Layer RT, Skolnick P, Bertha CM, Bandarage UK, Kuehne ME, Popik P. Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. Eur J Pharmacol 1996; 309(2): 159-65.
64. Koja T, Fukuzaki K, Kamenosono T, Nishimura A, Nagata R, Lukas SE. Inhibition of opioid abstinent phenomena by Ibogaine. Jpn J Pharmacol 1996; 71(S1): 89.
65. Parker LA, Burton P, McDonald RV, Kim JA, Siegel S. Ibogaine interferes with motivational and somatic effects of naloxoneprecipitated withdrawal from acutely administered morphine. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(2): 293-7.
66. Leal MB, Michelin K, Souza DO, Elisabetsky E. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N methyl-D-aspartate receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(5): 781-5.
67. Panchal V, Taraschenko OD, Maisonneuve IM, Glick SD. Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. Eur J Pharmacol 2005; 525(1-3): 98-104.
68. Ross S, Peselow E. Pharmacotherapy of addictive disorders. Clinical Neuropharmacology 2009; 32(5): 277-89.
69. Ward J, Rosenbaum C, Hernon C, McCurdy CR, Boyer EW. Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy? CNS Drugs 2011; 25(12): 999-1007.
70. Glick SD, Maisonneuve IM, Szumlinski KK. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids Chem Biol 2001; 56: 39-53.
71. Popik P, Layer RT, Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative antiaddictive drug. Pharmacol Rev 1995; 47(2): 235-53.
72. Mash DC, Kovera CA, Pablo J, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 2000; 914: 394-401.
73. Skolnick P. Ibogaine as a glutamate antagonist: relevance to its putative anti-addictive properties. Alkaloids Chem Biol 2001; 56: 55-62.
74. Helsley S, Rabin RA, Winter JC. Drug discrimination studies with ibogaine. Alkaloids Chem Biol 2001; 56: 63-77.
75. Pablo JP, Mash DC. Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding. Neuroreport 1998; 9(1): 109-14.
76. Nichols DE. Hallucinogens. Pharmacology and Therapeutics 2004; 101: 131-81.
77. Bowen WD, Vilner BJ, Williams W, et al. Ibogaine and its congeners are s2 receptor-selective ligands with moderate affinity. Eur J Pharmacol 1995; 271: R1-3.
78. Zubaran C, Shoaib M, Stolerman IP, Pablo J, Mash DC. Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain. Neuropsychopharmacol 1999; 21(1): 119-26.
79. Kamlet J. Safety issues and cardiac side-effects in the administration of ibogaine HCl [video on the Internet; cited 2012 Jun 15]. Presentation at International Drug Policy Reform Conference; 2009 Nov 14; Albuquerque, NM. Available from http://vimeo.com/7843758
80. Hoelen DW, Spiering W, Valk GD. Long QT syndrome induced by the anti-addiction drug ibogaine. N Engl J Med 2009; 360(3): 308-9.
81. Cantor M. Ibogaine: miracle cure? Truth Seeker 1990; 117(5) 23-6.
82. Sisko B. Interrupting drug dependency: a summary of 4 case histories. Bulletin of the Multidisciplinary Association for Psychedelic Studies (MAPS) 1994; 4(2) 15-23.
83. Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat 1994; 11(4): 379-85.
84. Luciano D. Observations on treatment with ibogaine. Am J Addictions 1998; 7(1): 89-90.
85. Kaplan CD, Ketzer E, de Jong J, de Vries M. Reaching a state of wellness: multistage explorations in social neuroscience. Social Neuroscience Bulletin 1993; 6(1): 6-7.
86. Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict 1999; 8(3): 234-42.
87. McClellan AT, Kushner H., Metger D., et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199-213.
88. Beck AT, Ward CH, Mendelson J., Mock J, Erbaugh J. An interview for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
89. Singleton EG. The HCQN-29: a short version of the Heroin Craving Questionnaire. Unpublished research 1996; Available from the Clinical Pharmacology and Therapeutics Research Branch, Intramural Research Program NIDA, 55 Nathan Shock Drive, Baltimore, MD 21224, USA.
90. Tiffany ST, Singleton E, Haertzen CA, Henningfield JE. The development of a cocaine craving questionnaire. Drug Alcohol Depend 1993; 34: 19-28.
91. Bastiaans E. Life after ibogaine: an exploratory study of the longterm effects of ibogaine treatment on drug addicts. Science Internship Report, Vrije Universiteit Amsterdam, 2004. [monograph on the Internet; cited 2012 May 30]. Available from http://www.ibogaine.org/ibogaine_udi_bastiaans
92. Krupitsky EM, Burakov AM, Romanov TN, Grinenko AY, Strassman RJ. Ketamine-assisted psychotherapy (KPT) of heroin addiction: immediate effects and six months follow-up. Hefter Review of Psychedelic Research 2001; 2: 88-101.
93. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacology and Therapeutics 2004; 102(2): 111-29.
94. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for narcotic addicts. Arch Gen Psych 1973; 28: 808-14.
95. Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012; 26(7): 994-1002.
96. Friedman H. The renewal of psychedelic research: implications for humanistic and transpersonal psychology. Humanistic Psychologist 2006; 34(1): 39-58.
97. Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 2008; 22: 621-32.
98. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 2011; 25: 1453-61.
99. Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev 2011; 4(1): 28-41.
100. Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services. Methadone mortality-a 2010 reassessment. Briefing paper delivered 2010 July 29-30; Washington, DC. Available from dpt.samhsa.gov/pdf/Methadone_Briefing_Paper.pdf; cited 2012 Jun 17.
101. De Maeyer J, Vanderplasschen W, Broekaert E. Quality of life among opiate-dependent individuals: a review of the literature. Int J Drug Policy 2010; 21(5): 364-80.
102. Hittner JB, Quello SB. Combatting substance abuse with ibogaine: pre-and post-treatment recommendations and an example of successive model fitting analyses. J Psychoactive Drugs 2004; 36(2): 191-9.
103. Fernandez JW, Fernandez RL. "Returning to the path": the use of iboga[ine] in an equatorial African ritual context and the binding of time, space, and social relationships. Alkaloids Chem Biol 2001; 56: 235-47.
104. Naranjo, C 1969. Psychotherapeutic possibilities of new fantasy-enhancing drugs. Clin Toxicol 2 (2): 209.
105. Mojeiko V, Brown TK, Gargour K, Jordan M. Observational study of the long-term efficacy of ibogaine-assisted treatment in participants with opiate addiction. Available from www.maps.org/research/ibogaine/
106. Noller G. Observational study of the long-term efficacy of ibogaine-assisted therapy in participants with opioid addiction. Available from www.maps.org/research/ibogaine/
107. McLellan AT, Cacciola JC, Alterman AI, Rikoon SH, Carise D. The Addiction Severity Index at 25: origins, contributions, and transitions. Am J Addictions 2006; 15(2): 113-24.
108. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13(3): 293-308.
109. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Pschopharmacol 2006; 187(3): 268-83.